|
|
| | C18 Galactosylceramide-d35 (d18:1/18:0-d35) Basic information |
| | C18 Galactosylceramide-d35 (d18:1/18:0-d35) Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Chloroform: soluble,Chloroform:Methanol (2:1): soluble,Ethanol: heated | | form | A solid |
| | C18 Galactosylceramide-d35 (d18:1/18:0-d35) Usage And Synthesis |
| Uses | β-Galactosyl-C18-ceramide-d35 is deuterium labeled β-Galactosyl-C18-ceramide. β-Galactosyl-C18-ceramide is a bioactive molecule that promotes the regulation of nerve cells, regulates protein kinase C activity, and affects hormone receptors. β-Galactosyl-C18-ceramide is widely used in neuroscience research to explore its effects on nerve cell growth and function. The regulatory function of β-Galactosyl-C18-ceramide makes it a potential application prospect in compound development and disease inhibition[1]. | | Biological Activity | C18 Galactosylceramide-d35 is intended for use as an internal standard for the quantification of C18 galactosylceramide by GC- or LC-MS. C18 Galactosylceramide is a naturally occurring sphingolipid that has been found in the cerebellum of rats and humans.1,2 It is selectively localized with cholesterol over potassium, sodium, or phosphocholine in rat cerebellum white matter.1 [Matreya, LLC. Catalog No. 1914] | | References | 1.Brner, K., Nygren, H., Hagenhoff, B., et al.Distribution of cholesterol and galactosylceramide in rat cerebellar white matterBiochem. Biophys. Acta.1761(3)335-344(2006)
2.Boutin, M., Sun, Y., Shacka, J.J., et al.Tandem mass spectrometry multiplex analysis of glucosylceramide and galactosylceramide isoforms in brain tissues at different stages of Parkinson DiseaseAnal. Chem.88(3)1856-1863(2016) |
| | C18 Galactosylceramide-d35 (d18:1/18:0-d35) Preparation Products And Raw materials |
|